Related Experiment Videos
Silencing polyglutamine degeneration with RNAi.
Nancy M Bonini1, Albert R La Spada
1Department of Biology and University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA. nbonini@sas.upenn.edu
Neuron
|December 13, 2005
Summary
Silencing disease genes with RNA-mediated interference (RNAi) can halt and potentially reverse neurodegenerative polyglutamine diseases. This therapeutic approach targets dominant alleles causing these inherited conditions.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Nine inherited neurodegenerative diseases are linked to expanded CAG repeats encoding glutamine.
- These polyglutamine diseases exhibit significant pathology in affected individuals.
Purpose of the Study:
- To explore the therapeutic potential of gene silencing for polyglutamine diseases.
- To investigate RNA-mediated interference (RNAi) as a strategy to target dominant disease alleles.
Main Methods:
- Utilized animal models with established disease pathology.
- Employed RNA-mediated interference (RNAi) to silence disease-encoding transgenes.
Main Results:
- Demonstrated that shutting off transgene expression arrested disease progression.
- Confirmed the feasibility of allele-specific silencing in disease models.
Conclusions:
- RNA-mediated interference (RNAi) represents a promising therapeutic strategy for polyglutamine diseases.
- Gene silencing offers a pathway for arresting and potentially reversing neurodegenerative disease processes.